Epidermicin NI01 effective for drug-resistant skin infections
19 June 2026We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
We are pleased to share the publication of a new peer-reviewed study in the Journal of Antimicrobial Chemotherapy – Antimicrobial…
From 17th-22nd April, Mat and Vicky headed to Munich, Germany for ESCMID GLOBAL 2026
Last week, CSO Mat Upton and CEO Gordon Barker travelled to Basel, Switzerland for the BEAM Alliance 10th AMR meeting.…
On 14th December, CSO Mat Upton was invited to attend the Final Forum of the Saudi Biotechnology Accelerator (SBA) in…
Amprologix celebrates research excellence at the University of Plymouth as CSO Professor Mat Upton presents the Research Excellence Award to…
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.
